Last updated: April 1, 2026
What is the drug associated with NDC 70752-0104?
NDC 70752-0104 is identified as SpiroMeta (metformin hydrochloride extended-release tablets). It is a generic formulation of metformin for type 2 diabetes management.
Market Overview
Market Size and Demand Drivers
The global diabetes drug market, valued at approximately USD 62 billion in 2022, is projected to grow at a compound annual growth rate (CAGR) of 7% through 2028, driven by rising diabetes prevalence worldwide.
Within this market, metformin remains the most prescribed first-line treatment. According to the American Diabetes Association (ADA), over 150 million individuals globally used metformin in 2022, representing around 60% of all oral antidiabetics.
Key Competitors and Market Participants
Major competitors include:
- Glucophage (brand name for metformin by Merck/ANIP)
- Fortamet (extended-release by Jansen Pharmaceuticals)
- Glumetza (by Bionpharma via license from DepriMed)
- Several generic manufacturers, including Teva, Mylan, and Sandoz.
Market share favors generic formulations due to lower prices and widespread prescribing practices.
Patent and Regulatory Status
This specific NDC is a generic extended-release formulation, which took patent expiry in 2017. Since then, multiple manufacturers have entered the market.
The Drug Enforcement Agency (DEA) classifies metformin as a non-controlled substance. Regulatory agencies, including the FDA, approve generic versions via Abbreviated New Drug Applications (ANDAs), which have high approval rates due to established bioequivalence.
Pricing Landscape
Historical Pricing Data
| Product |
Typical Wholesale Acquisition Cost (WAC) |
Estimated Medicaid Reimbursement |
Average Retail Price (AR) |
| Brand (Glucophage XR) |
USD 60-70 per 30 tablets (500 mg) |
USD 25-35 |
USD 75 |
| Generic (NDC 70752-0104) |
USD 8-12 per 30 tablets (500 mg) |
USD 3-7 |
USD 16 |
Prices fluctuate based on dosage, manufacturer, and pharmacy discounts. Extended-release formulations typically command a premium over immediate-release versions but remain competitive within generics.
Price Trends and Factors
- Post-patent expiry: Prices for generics consistently decline over time due to increased competition.
- Market penetration: Broad adoption in outpatient clinics and primary care enhances volume.
- Formulation preferences: Extended-release options are increasingly favored for improved compliance and reduced gastrointestinal side effects.
Impact of New Entrants and Regulatory Changes
Increasing generic supply suppresses prices. New formulations such as controlled-release or combination products could influence price dynamics, but currently, extended-release metformin remains a low-cost, high-volume drug.
Market Share and Volume Projections
Volume Growth
Annual prescriptions for metformin in the US exceed 60 million units as of 2022, with a projected 4% annual growth linked to increasing diabetes prevalence.
Market Share Projections (Next 5 Years)
| Scenario |
Estimated Market Share of NDC 70752-0104 |
Notes |
| Conservative |
25% |
Due to competition from other generics and alternative formulations |
| Moderate |
35% |
Assumes increased physician familiarity and formulary inclusion |
| Optimistic |
45% |
Driven by preferences for extended-release formulations and price advantages |
Revenue Estimates
Assuming an average of 10 million units sold annually at an average wholesale price of USD 10 per bottle, revenue potential stands at USD 100 million annually for this NDC.
Price Projection Outlook
| Year |
Price per 30 Tablets (500 mg) |
Comments |
| 2023 |
USD 10 |
Based on current market averages and competition |
| 2025 |
USD 8-9 |
Expected decline as additional generic entrants stabilize prices |
| 2030 |
USD 7-8 |
Further price compression anticipated with increased volume and biosimilar entry |
Note: Actual prices will depend on supply chain factors, payer negotiations, and regional variations.
Conclusion
The market for NDC 70752-0104 remains competitive due to multiple generic players. Prices are set to decline gradually over the next five years with sustained high demand for metformin's extended-release formulation. Volume growth in primary care settings supports stable revenue streams, but price erosion is expected as competition intensifies.
Key Takeaways
- NDC 70752-0104 applies to a widely prescribed extended-release metformin generic.
- The global diabetes market is expanding at a CAGR of 7%, with high shared demand for metformin.
- Price points are consolidating around USD 8-12 wholesale per 30-tablet pack, trending downward.
- Market share projections vary between 25-45% over five years based on formulary inclusion and physician preference.
- Revenues from this NDC could reach USD 100 million annually with increasing volume but decreasing prices.
FAQs
1. Will prices for this generic drug decrease further?
Yes. As more manufacturers enter the market, prices tend to decline due to competition. The trend suggests a 10-20% reduction over the next five years.
2. What factors influence the market share of this extended-release metformin?
Physician prescribing habits, formulary placements, patient preferences for extended-release formulations, and pricing strategies impact market penetration.
3. How does the demand for extended-release formulations compare to immediate-release metformin?
Extended-release formulations are often prescribed for better gastrointestinal tolerance and adherence, but immediate-release versions dominate due to lower cost and simplicity.
4. Are there upcoming regulatory changes that could affect pricing or availability?
Current regulations favor generic substitution. No significant policy changes are expected immediately, but patent litigations or biosimilar entries could influence future dynamics.
5. What future trends could impact the market for this drug?
Development of combination therapies, biosimilars, and newer diabetes drugs could shift demand patterns; however, metformin’s low cost ensures persistent baseline demand.
References
[1] IMS Health (2022). Global Diabetes Market Data.
[2] American Diabetes Association (2022). Economic Costs of Diabetes.
[3] FDA (2022). ANDA Approvals and Generic Market Data.
[4] IQVIA (2023). Prescription Trends for Diabetes Medications.
[5] EvaluatePharma (2022). Price Trends and Future Market Projections.
